Shionogi Sets Up In Europe, To Develop Pipeline Before The "Crestor Cliff"
This article was originally published in The Pink Sheet Daily
Anticipating the loss of royalties from Crestor in the next five years, Japanese innovator Shionogi continues its globalization process with a U.K. headquarters to pursue development of its late-stage research pipeline in Europe.
You may also be interested in...
Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.
Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning
TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)
TOKYO - Shionogi & Co. Ltd. is fighting a two-front battle, recovery from the March 2011 earthquake and tsunami in Northern Japan and restructuring of its U.S. acquisition. The company formulated a mid-term plan to address ways to buffer the September 2016 patent loss of Crestor (rosuvastatin), by far the company's most important drug, but setbacks in the U.S. raise doubts about the company's ability to counter the patent cliff